BridgeBio Pharma, Inc. (BBIO)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Total revenues, net | 110,565 | 2,732 | ||
| Restructuring charges, total | - | 4,621 | ||
| Selling, general and administrative | 129,154 | 68,819 | ||
| Restructuring, impairment and related charges | 805 | - | ||
| Research and development | 111,231 | 120,444 | ||
| Cost Of License Services And Royalty Revenue | 805 | - | ||
| Cost Of Goods Sold | 2,848 | - | ||
| Total cost of revenues | 3,653 | 598 | ||
| Total operating costs and expenses | 244,843 | 194,482 | ||
| Loss from operations | -134,278 | -191,750 | ||
| Other income (expense), net | 6,548 | 1,797 | ||
| Interest income | 3,898 | 3,296 | ||
| Interest expense | 37,637 | 23,061 | ||
| Net loss from equity method investments | -20,189 | -6,563 | ||
| Losses on extinguishments of debt | - | - | ||
| Gain on deconsolidation of a subsidiary | - | 52,027 | ||
| Total other income (expense), net | -47,380 | 27,496 | ||
| Loss before income taxes | -181,658 | - | ||
| Income tax expense | 2,100 | - | ||
| Net loss | -183,758 | -164,254 | ||
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | -1,855 | -2,214 | ||
| Net loss attributable to common stockholders of bridgebio | -181,903 | -162,040 | ||
| Earnings per share, basic, total | -0.95 | -0.86 | ||
| Earnings per share, diluted, total | -0.95 | -0.86 | ||
| Weighted average number of shares outstanding, basic, total | 190,517,215 | 188,510,372 | ||
| Weighted average number of shares outstanding, diluted, total | 190,517,215 | 188,510,372 | ||